Roger Longman
Managing Partner
Windhover Information

Roger Longman is a Managing Partner at Windhover Information, an Elsevier business. He has been involved with the health care industry for more than 20 years.

In 1983, Mr. Longman joined The Wilkerson Group as a writer covering the pharmaceutical and biotech industries for IN VIVO: The Business & Medicine Report. In 1989, Longman along with David Cassak led a buyout of the Wilkerson Group's publications division, which they moved to Connecticut and renamed Windhover Information Inc.

Since then Mr. Longman and Mr. Cassak have launched several new ventures including

• Start-Up: Windhover’s Review of Emerging Medical Ventures™;
• Strategic Transactions Database, the industry’s most comprehensive and detailed database of industry M&A, alliances and financings;
• The RPM Report: Regulation • Policy • Market Access™, an analysis of key marketing, strategy and R&D implications of the changes in Washington at CMS and FDA;
• and a series of senior-executive conferences in corporate strategy, business development, R&D, and finance.

In 2004, Windhover acquired Medtech Insight, an information company covering the medical device field through a market-leading newsletter, a series of in-depth market reports, and a number of conferences. In 2008, Windhover was acquired by Reed Elsevier.

Under Elsevier, Mr. Longman runs a newly-created business unit that features several leading publications serving biopharma executives, including IN VIVO, Start-Up, The RPM Report and “The Pink Sheet,” “Pink Sheet Daily” and PharmAsia News, among others. In addition, the new unit will oversee biopharmaceutical conferences and partnering events, as well as and biopharmaceutical content in Windhover’s M&A, alliance, and financing transactions database.

Over the years, Mr. Longman has become recognized as one of the leading experts in biopharmaceutical strategy and dealmaking. He is often asked to speak at many key industry events organized by important trade organizations like the Biotechnology Industry Organization (BIO), investment banks, venture capital firms and leading pharma and biotech companies. He lectures regularly at several leading universities. Mr. Longman completed his BA at Cornell University and an MA at the University of North Carolina at Chapel Hill, and then taught for three years at the European division of the University of Maryland.

Robin Arnold
VP, Global Practice Leader for Product & Portfolio Strategy
SDG Life Sciences, a unit of IMS

Robin Arnold has directed engagements throughout Europe, North America, and Asia, developing creative solutions to some of the most challenging business situations in Life Sciences.

He has worked with major pharmaceutical companies to develop worldwide R&D portfolio evaluation and management capability based on innovative methodologies, group processes and decision systems. As a result, clients have created enormous value at the individual project, therapeutic area and development portfolio levels by terminating or redirecting value-eroding projects, reallocating corporate resources across therapeutic areas and creating new strategy development processes. This value creation has been recognized by analysts and shareholders.

Mr. Arnold has supported some of the world’s largest companies in their corporate strategies for the health market, including their most critical decisions about acquisitions, divestitures, technology acquisition and geographic focus. He helped one of the world’s leading technology companies focus its business around health care and supported a leading US life science company in redirecting its corporate business portfolio. Results included billions of dollars in divestitures and acquisitions, exits from major business areas, and development of a major therapeutic area that now leads the company’s growth.

Since 1998, Mr. Arnold has taken a special interest in Indian and Chinese pharmaceutical markets, supporting several leading Indian companies with major transformations in process and organization, as well as generics strategies for local and international companies. This has included geographic and product portfolios, acquisitions and licensing and competency development in biogenerics, APIs, bulk and branded generics.

Mr. Arnold speaks at industry forums, business schools and professional associations on strategy in life sciences and has published several professional papers. He holds an MBA from the Amos Tuck School of Dartmouth College and an MA in law from Jesus College, Cambridge.